
Ameet Nathwani, Dewpoint CEO (Viva Technology/Sipa/L.Chamussy, Sipa via AP Images)
SoftBank leads $150M round into Dewpoint as condensate biotech nears clinic
In another market, Dewpoint Therapeutics may have gone public about now and raised a princely sum.
Although they’re still around two years from human trials, the biotech already has blue-chip VC backers, three Big Pharma partnerships, and a compelling story about being the first and biggest entrant to a new field of biology. But Wall Street isn’t buying much of anything these days.
So Dewpoint will have to settle for the next best thing: a venture capital firm that often acts as if it has as much money as Wall Street — SoftBank.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters